Number of participants in pilot study for DCS in chronic pain (count)

P-value from post-hoc analysis in pilot study for DCS in chronic pain (p-value)

Number of participants in US Department of Defense-sponsored efficacy trial for DCS in chronic pain (count)

Number of manufacturing lots completed for NRX-100 (count)

Shelf life of NRX-100 manufacturing lots (years)

Number of manufacturing lots completed for NRX-101 (count)

Shelf life of NRX-101 manufacturing lots (months)

Potential licensing milestones for NRX-100 (USD millions)

Sliding scale royalty range for NRX-100 (percentage)

Minimum Inhibitory Concentration of Lurasidone for E. coli 35218 (μg/mL)

Minimum Inhibitory Concentration of DCS for E. coli 35218 (μg/mL)

Minimum Inhibitory Concentration of DCS + Lurasidone for E. coli 35218 (μg/mL)

Minimum Inhibitory Concentration of Lurasidone for E. coli 25922 (μg/mL)

Minimum Inhibitory Concentration of DCS for E. coli 25922 (μg/mL)

Minimum Inhibitory Concentration of DCS + Lurasidone for E. coli 25922 (μg/mL)

Minimum Inhibitory Concentration of Lurasidone for E. coli 700928 (μg/mL)

Minimum Inhibitory Concentration of DCS for E. coli 700928 (μg/mL)

Minimum Inhibitory Concentration of DCS + Lurasidone for E. coli 700928 (μg/mL)

Minimum Inhibitory Concentration of Lurasidone for E. coli 700336 (μg/mL)

Minimum Inhibitory Concentration of DCS for E. coli 700336 (μg/mL)

Minimum Inhibitory Concentration of DCS + Lurasidone for E. coli 700336 (μg/mL)

Minimum Inhibitory Concentration of Lurasidone for E. coli 2469 (μg/mL)

Minimum Inhibitory Concentration of DCS for E. coli 2469 (μg/mL)

Minimum Inhibitory Concentration of DCS + Lurasidone for E. coli 2469 (μg/mL)

Minimum Inhibitory Concentration of Lurasidone for E. coli Xen 16 (μg/mL)

Minimum Inhibitory Concentration of DCS for E. coli Xen 16 (μg/mL)

Minimum Inhibitory Concentration of DCS + Lurasidone for E. coli Xen 16 (μg/mL)

Minimum Inhibitory Concentration of Lurasidone for P. aeruginosa PA01 (μg/mL)

Minimum Inhibitory Concentration of DCS for P. aeruginosa PA01 (μg/mL)

Minimum Inhibitory Concentration of DCS + Lurasidone for P. aeruginosa PA01 (μg/mL)

Minimum Inhibitory Concentration of Lurasidone for P. aeruginosa 27853 (μg/mL)

Minimum Inhibitory Concentration of DCS for P. aeruginosa 27853 (μg/mL)

Minimum Inhibitory Concentration of DCS + Lurasidone for P. aeruginosa 27853 (μg/mL)

Minimum Inhibitory Concentration of Lurasidone for P. aeruginosa Xen 41 (μg/mL)

Minimum Inhibitory Concentration of DCS for P. aeruginosa Xen 41 (μg/mL)

Minimum Inhibitory Concentration of DCS + Lurasidone for P. aeruginosa Xen 41 (μg/mL)

Minimum Inhibitory Concentration of Lurasidone for P. aeruginosa BAA 3105 (μg/mL)

Minimum Inhibitory Concentration of DCS for P. aeruginosa BAA 3105 (μg/mL)

Minimum Inhibitory Concentration of DCS + Lurasidone for P. aeruginosa BAA 3105 (μg/mL)

Minimum Inhibitory Concentration of Lurasidone for K. pneumoniae 1705 (μg/mL)

Minimum Inhibitory Concentration of DCS for K. pneumoniae 1705 (μg/mL)

Minimum Inhibitory Concentration of DCS + Lurasidone for K. pneumoniae 1705 (μg/mL)

Minimum Inhibitory Concentration of DCS for A. baumannii 19606 (μg/mL)

Minimum Inhibitory Concentration of DCS + Lurasidone for A. baumannii 19606 (μg/mL)

Minimum Inhibitory Concentration of Lurasidone for A. baumannii 1605 (μg/mL)

Minimum Inhibitory Concentration of DCS for A. baumannii 1605 (μg/mL)

Minimum Inhibitory Concentration of DCS + Lurasidone for A. baumannii 1605 (μg/mL)

Royalty rate if product is not covered by a Valid Claim (percentage)

Royalty rate if product is covered by a Valid Claim (percentage)

Maximum sub-license royalty cap (percentage)

Number of psychiatry centers under non-binding letters of intent (count)

Number of additional psychiatry centers under negotiation (count)

Milestone payment for End of Phase I Clinical Trials of Licensed Product (USD)

Milestone payment for End of Phase II Clinical Trials of Licensed Product (USD)

Milestone payment for End of Phase III Clinical Trials of Licensed Product (USD)

Milestone payment for First Commercial Sale of Licensed Product in the U.S. (USD)

Milestone payment for First Commercial Sale of Licensed Product in Europe (USD)

Milestone payment if Annual Revenues reach $100,000,000 (USD)

ac785964170ccb2962ed5f282f2f0b5603898af3baef34d34f56819df35d9500

Cash and cash equivalents (USD, thousands)

Prepaid expenses and other current assets (USD, thousands)

Total current assets (USD, thousands)

Other assets (USD, thousands)

Total assets (USD, thousands)

Accounts payable (USD, thousands)

Accrued and other current liabilities (USD, thousands)

Accrued clinical site costs (USD, thousands)

Convertible note payable and accrued interest – short term (USD, thousands)

Warrant liabilities (USD, thousands)

Total current liabilities (USD, thousands)

Convertible note payable and accrued interest – long term (USD, thousands)

Total liabilities (USD, thousands)

Preferred stock, $ 0.001 par value (USD, thousands)

Common stock, $ 0.001 par value (USD, thousands)

Additional paid-in capital (USD, thousands)

Accumulated deficit (USD, thousands)

34135363501a184e32d23553699a0c2900c3b245b15fb5c710bf858c21fc8d93

Research and development (USD, thousands)

General and administrative (USD, thousands)

Settlement (income) expense (USD, thousands)

Total operating expenses (USD, thousands)

Loss from operations (USD, thousands)

Interest income (USD, thousands)

Interest expense (USD, thousands)

Change in fair value of convertible notes payable (USD, thousands)

Change in fair value of warrant liabilities (USD, thousands)

Loss on convertible note redemptions (USD, thousands)

Total other (income) expense (USD, thousands)

Net loss (USD, thousands)

Net loss per share - Basic and Diluted (USD)

Weighted average common shares outstanding - Basic and Diluted (shares)

4bc447e29f6b6e6de11a70960ed6543c4531f9a40172d2bc7aa76d6becfca119

Net loss [in thousands]

Adjustments to reconcile net loss to net cash used in operating activities: Depreciation expense [in thousands]

Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation [in thousands]

Adjustments to reconcile net loss to net cash used in operating activities: Change in fair value of warrant liabilities [in thousands]

Adjustments to reconcile net loss to net cash used in operating activities: Change in fair value of convertible promissory notes [in thousands]

Adjustments to reconcile net loss to net cash used in operating activities: Loss on convertible note redemptions [in thousands]

Adjustments to reconcile net loss to net cash used in operating activities: Expense for debt issuance costs due to fair value election on Anson Notes [in thousands]

Changes in operating assets and liabilities: Prepaid expense and other assets [in thousands]

Changes in operating assets and liabilities: Accounts payable [in thousands]

Changes in operating assets and liabilities: Accrued expense and other liabilities [in thousands]

Net cash used in operating activities [in thousands]

CASH FLOWS FROM INVESTING ACTIVITIES: Purchase of computer equipment [in thousands]

Net cash used in investing activities [in thousands]

CASH FLOWS FROM FINANCING ACTIVITIES: Repayment of convertible note [in thousands]

CASH FLOWS FROM FINANCING ACTIVITIES: Repayment of insurance loan [in thousands]

CASH FLOWS FROM FINANCING ACTIVITIES: Expense for debt issuance costs due to fair value election on Anson Notes [in thousands]

CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from Anson convertible notes, net [in thousands]

CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from issuance of common stock and warrants, net of issuance costs [in thousands]

CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from issuance of common stock and warrants issued in private placement, net of issuance costs [in thousands]

Net cash provided by financing activities [in thousands]

Net decrease in cash and cash equivalents [in thousands]

Supplemental disclosure of cash flow information: Cash paid for interest [in thousands]

Supplemental disclosure of cash flow information: Cash paid for taxes [in thousands]

Non-cash investing and financing activities: Issuance of common stock as principal and interest repayment for convertible notes [in thousands]

Non-cash investing and financing activities: Issuance of common stock warrants as offering costs [in thousands]

Non-cash investing and financing activities: Conversion of Series A preferred stock into common stock [in thousands]

Non-cash investing and financing activities: Warrants issued pursuant to the Alvogen Agreement amendment [in thousands]

2bd0b0b1dbf0f67f0b8963f059eda9a35bbaf3dfa986cfee68011f08bc8131c3

NRX Pharmaceuticals (NRXP)

Financials